“
TL;DR
This study is a subanalysis of the FIDELITY trial, which pooled data from two phase 3 randomized trials.
JAMA Cardiology · 15 authors, 20 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This study is a subanalysis of the FIDELITY trial, which pooled data from two phase 3 randomized trials.
This study is a subanalysis of the FIDELITY trial, which pooled data from two phase 3 randomized trials. A key driver of this benefit was a reduction in hospitalizations for heart failure. The authors also performed a simulation to estimate the number of potentially preventable cardiovascular events in the US population eligible for finerenone.